Slides
Page 1
© Genmab 2026 Genmab Investor Event October 28, 2026
Page 2
© Genmab 2026 Forward looking statement This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Further, certain forward looking statements are based upon assumptions of future events which may not prove to be accurate. The forward looking statements in this document speak only as at the date of this presentation. Genmab does not undertake any obligation to update or revise forward looking statements in this presentation nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. For Investor audience only. Not for public information or use. Not for promotional use 2
Page 3
© Genmab 2026 3 Three Positive Phase 3 Trials Position Genmab for Its Next Growth Cycle 1 Epcoritamab (EPKINLY®/TEPKINLY®) Positive EPCORE® DLBCL-2 topline establishes a potential new frontline opportunity in DLBCL 2 Rina-S® Positive RAINFOL -02 topline and consistent Phase 2 results deliver category- defining data in PROC 3 Petosemtamab Positive LiGeR-HN1 topline establishes the 1L HNSCC opportunity; ESMO Phase 2 data support expansion into CRC 4 Portfolio Positioned for Growth Three assets create multiple potential launch opportunities in 2027 and path to long-term growth Phase 3 results are reported at topline. Until full results are presented at future medical meetings, Phase 2 data provide clinical context for each program. DLBCL = diffuse large B-cell lymphoma; PROC = platinum resistant ovarian cancer; CRC = colorectal cancer; HNSCC = head and neck squamous cell carcinoma EPKINLY® is being co-developed and co-promoted by Genmab and AbbVie For Investor audience only. Not for public information or use. Not for promotional use
Page 4
© Genmab 2026 Delivering on Our Commitments: Multiple Phase 3 Readouts to Drive Potential 2027 Launches For Investor audience only. Not for public information or use. Not for promotional use Rina-S® • Ph 2 2L+ PROC (RAINFOL -01) • Ph 3 2L+ PROC (RAINFOL -02) October 2026 EPKINLY® • Ph 3 1L DLBCL (EPCORE® DLBCL-2) October 2026 • Ph 3 2L+ DLBCL mono (EPCORE ® DLBCL-1) January 2026 Petosemtamab • Ph 3 1L r/m HNSCC (LiGeR-HN1) October 2026 • Ph 3 2L/3L r/m HNSCC (LiGeR-HN2) Q1 2027 4 • Ph 3 2L+ DLBCL combo + len (EPCORE® DLBCL-4) June 2026
Page 5
© Genmab 2026 01. EPKINLY®: Potential to Reshape Frontline DLBCL Treatment EPCORE® DLBCL-2: First Phase 3 bispecific combination to improve PFS in newly diagnosed DLBCL For Investor audience only. Not for public information or use. Not for promotional use
Page 6
© Genmab 2026 6 EPCORE® DLBCL-2: First Phase 3 Bispecific Combination to Improve PFS in Newly Diagnosed DLBCL CI = confidence interval; HR = hazard ratio; IPI = International Prognostic Index; PFS = progression-free survival; R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone. For Investor audience only. Not for public information or use. Not for promotional use Phase 3 results are reported at topline; further details will be presented at an appropriate medical conference. TOPLINE RESULTS Risk of progression or death reduced by 51% (HR 0.49 [95% CI 0.36, 0.67]; p < 0.0001) Statistically significant and clinically meaningful improvement in PFS in DLBCL patients with an IPI score of 2 to 5 Generally well tolerated; safety consistent with the known profiles of epcoritamab and R-CHOP TRIAL DESIGN Global, randomized, open-label Phase 3 in newly diagnosed large B-cell lymphoma (IPI 2–5); fixed-duration subcutaneous epcoritamab + R-CHOP vs R-CHOP NEXT STEPS Full data to be presented at a future medical meeting; Genmab and AbbVie plan to engage global regulatory authorities Potential to Reshape Frontline DLBCL Treatment
Page 7
© Genmab 2026 Expanding EPKINLY®’s Reach 12K 3L+ DLBCL1 Addressable Market at First Launch +6K 3L+ FL2 Approved +9K 2L+ FL3 Approved +21K 2L+ DLBCL Potential Launch 20274 +70K 1L DLBCL Potential Launch 20274 +28K 1L FL Phase 3 Ongoing 146K Total Addressable Patient Population Addressable patients (EU5, US, JP) from first launch to full potential across DLBCL and FL DLBCL FL Source: Genmab Internal Analysis, based on 2024 patient numbers, US, JP and EU5 1. FDA approved May 2023, EC and JP approved Sept. 2023; 2. FDA approved June 2024, EC approved Aug 2024, JP approved Feb 2025; 3. FDA approved Nov 2025, EC approved Jul 2026, JP approved September 2026. 4. Subject to regulatory approvals. EPKINLY® is being co-developed and co-promoted by Genmab and AbbVie 7 Potential to Become the Core Therapy in B-cell Malignancies For Investor audience only. Not for public information or use. Not for promotional use
Page 8
© Genmab 2026 EPKINLY®: Three Phase 3 Readouts in Twelve Months Broad Phase 3 Program to Reach Majority of B-Cell Lymphoma Patients 8 Program Indication Status Addressable Patient Population* EPKINLY® 1L DLBCL (EPCORE® DLBCL-2) Pos. Topline Oct. 2026 70,000 2L+ DLBCL (EPCORE® DLBCL-1) Topline Jan. 2026 2L+ DLBCL (EPCORE® DLBCL-4) Pos. Topline Jun. 2026 21,000 1L FL (EPCORE® FL-2) Ongoing 28,000 2L+ FL (EPCORE® FL-1) Approved in US 9,000 *Genmab Internal, US, JP and EU5 3 Phase 3 readouts in 2026 January, June, October 146,000 patients addressable across the DLBCL and FL franchise* >$3Bn peak sales opportunity For Investor audience only. Not for public information or use. Not for promotional use
Page 9
© Genmab 2026 02. Rina-S®: A Wholly Owned Gynecologic Oncology Franchise Updated data from the Phase 2 RAINFOL -01 study and positive topline data from the Phase 3 RAINFOL -02 study support the potential of Rina-S in PROC For Investor audience only. Not for public information or use. Not for promotional use
Page 10
© Genmab 2026 10 RAINFOL -01 Phase 2 Cohort: Durable Responses Observed Regardless of FRα Level or Prior Treatment with Mirvetuximab Efficacy 45.9% confirmed ORR (n=109) 12.1 mo median duration of response 9.5 mo median PFS 66.6% Survival rate at 12 months ORR 51.4% in mirvetuximab-naïve and 34.4% after prior mirvetuximab Responses seen across FRα expression levels, including undetectable FRα expression Disease control rate 94.5% Safety 0 fatal TEAEs (grade 5) 1.8% treatment-related discontinuations; 5.5% overall No signal ocular events or neuropathy No signal ILD or stomatitis Grade 3–4 TEAEs: 66.1% overall; 45.9% treatment-related Serious TEAEs: 31.2% overall; 15.6% treatment-related Non-hematological events were mainly low-grade GI events (nausea 67.9%; fatigue 57.8%) Source: Lee et al., Rinatabart Sesutecan (Rina-S®) for Patients With Platinum-resistant Ovarian Cancer: First Efficacy and Safety Results From the Phase 2 Cohort of The RAINFOL-01 Study, IGCS 2026. DOR in 50 responders. ORR = objective response rate. Phase 2 results do not predict Phase 3 outcomes. For Investor audience only. Not for public information or use. Not for promotional use RAINFOL -01 Phase 2 data provide further support for RAINFOL -02 in PROC.
Page 11
© Genmab 2026 11 RAINFOL -02: Rina-S® Improved PFS and OS in PROC Benefit in Patients Observed Irrespective of FRα Level or Prior Treatment with Mirvetuximab TOPLINE RESULTS Statistically significant and clinically meaningful improvement in PFS and OS vs investigator’s choice chemotherapy in PROC TRIAL DESIGN Randomized, open-label, global Phase 3; 584 patients with platinum-resistant ovarian cancer; Rina-S® vs investigator’s choice chemotherapy First of 6 Rina-S® Phase 3 trials to read out; building a wholly owned gyn-onc franchise ITT = intent-to-treat, all randomized patients with PROC, regardless of FRα expression; PAS = primary analysis set, mandated patients with FRα expression ≥75% PS2+ to have been treated with mirvetuximab; OS = overall survival; Investigator’s choice chemo = PLD, Paclitaxel, Gemcitabine, Topotecan. Phase 3 results are reported at topline; further details will be presented at an appropriate medical conference. For Investor audience only. Not for public information or use. Not for promotional use SAFETY Consistent with the known Rina-S profile; no new safety signals or unexpected safety concerns NEXT STEPS Data to be submitted for presentation at a future medical meeting and discussed with regulatory authorities ITT population (N=584): 71% reduction in the risk of disease progression or death (HR 0.29; 95% CI, 0.23-0.37; p<0.0001) OS: (HR 0.43; 95% CI, 0.31–0.59; p<0.0001) PAS sub-population (N=492): 67% reduction in the risk of disease progression or death (HR 0.33; 95% CI, 0.26–0.42; p<0.0001) OS: (HR 0.44; 95% CI, 0.31–0.63; p<0.0001)
Page 12
© Genmab 2026 Rina-S®: Potential Best-in-Class ADC with Broad Phase 3 Program Advances Gyn-Onc Portfolio with Development across Ovarian and Endometrial Cancers 12 Program Indication Status Addressable Patient Population* Rina-S® PROC (RAINFOL -02) Pos. Topline Oct. 2026 40,000 2L+ EC (RAINFOL -03) Recruiting 14,000 1L pMMR EC (RAINFOL -08) Announced 2L PSOC maintenance (RAINFOL -04) Recruiting 25,0002L PSOC platinum-doublet chemo replacement (RAINFOL -07) Recruiting 1L OC (RAINFOL -10) Not yet recruiting *Genmab Internal, US, JP and EU5, diagnosed systemic drug-treated patients before FR-α or MMR testing. 6 Phase 3 trials announced/initiated since ProfoundBio acquisition in 2024 79,000 patients addressable across the Rina-S® Phase 3 program* >$2Bn peak sales opportunity . For Investor audience only. Not for public information or use. Not for promotional use
Page 13
© Genmab 2026 03. Petosemtamab Anchor in HNSCC, Expand in CRC Positive LiGeR-HN1 topline the basis for potential 2027 approval, and launch in 1L HNSCC; ESMO Phase 2 data support two Phase 3 trials in CRC For Investor audience only. Not for public information or use. Not for promotional use
Page 14
© Genmab 2026 14 Phase 2 Data: 1L HNSCC: Deep, Durable Activity Regardless of HPV Status For Investor audience only. Not for public information or use. Not for promotional use Source: Daste et al., Petosemtamab ± Pembrolizumab in R/M HNSCC, ESMO 2026. Patients: Genmab analysis, US, EU, Japan. Phase 2 results do not predict Phase 3 outcomes. 1L HNSCC with pembrolizumab PD-L1+ r/m; 45 treated, 43 efficacy-evaluable 63% confirmed ORR (27 of 43) 19% CR rate 9.0 mo median PFS 28.2 mo median OS SAFETY Manageable safety profile, with no unexpected safety signals identified with extended follow-up. Grade ≥3 TEAEs: 60%; no grade 5 treatment-related TEAEs or significant overlapping toxicities PHASE 3 LINK LiGeR-HN1 tests petosemtamab + pembrolizumab vs pembrolizumab in about 700 patients with 1L PD-L1+ r/m HNSCC, with dual primary endpoints of ORR and OS. About 41K addressable patients in 1L HNSCC. Phase 2 data provide further support for LiGeR-HN in 1L HNSCC.
Page 15
© Genmab 2026 15 LiGeR-HN1: Clinically Meaningful Improvement in OS and ORR in 1L HNSCC Regardless of HPV Status TOPLINE RESULTS Dual primary endpoints met: statistically significant and clinically meaningful improvement in OS and ORR at the interim analysis vs. pembrolizumab, regardless of HPV status TRIAL DESIGN Global, randomized Phase 3 trial, approx. 700 patients with 1L r/m PD-L1+ HNSCC; petosemtamab + pembrolizumab vs pembrolizumab; dual primary endpoints ORR and OS First randomized Phase 3 study in 1L r/m HNSCC to demonstrate a statistically significant OS benefit over pembrolizumab with a chemo-free regimen. Phase 3 results are reported at topline; further details will be presented at an appropriate medical conference. For Investor audience only. Not for public information or use. Not for promotional use NEXT STEPS Full data to be presented at a future medical meeting; Genmab plans to engage regulatory authorities (HR 0.50 [95% CI, 0.37, 0.67]; p<0.0001) in 1L r/m patients with PD-L1+ HNSCC ORR: odds ratio 3.17 (95% CI, 2.06, 4.89; p<0.0001) Safety consistent with the Phase 2 profile. Reducing the risk of death by 50%
Page 16
© Genmab 2026 16 Phase 2 Data: Robust, Durable Responses Across Key Patient Subgroups, Including in Liver Metastases For Investor audience only. Not for public information or use. Not for promotional use Source: Khushman et al., Petosemtamab Plus Chemotherapy in mCRC, ESMO 2026. ORR includes confirmed and unconfirmed responses. Patients: Genmab analysis, US, EU, Japan. Phase 2 does not predict Phase 3. CRC with chemotherapy 79 treated; efficacy-evaluable: 1L n=40, 2L n=30 81% ORR, left-sided 1L tumors 67% ORR, 2L 95% / 93% DCR, 1L / 2L 2 Phase 3 trials started SAFETY No unexpected safety signals emerged; the profile remained consistent with the known profiles of the individual agents. No grade 5 treatment-related TEAEs and no discontinuations due to IRRs were reported PHASE 3 PROGRAM LiGeR-CRC1 (1L) and LiGeR-CRC2 (2L+) are recruiting. About 179K addressable patients across 1L and 2L+ CRC (RAS BRAF wild type). CRC gives petosemtamab a second growth path beyond HNSCC, with two Phase 3 trials underway
Page 17
© Genmab 2026 Petosemtamab: Data Establish HNSCC as Anchor Opportunity Two Phase 3 CRC Trials Provide Expansion Potential 17 Program Indication Status Addressable Patient Population* Petosemtamab 1L HNSCC (LiGeR-HN1) PositiveTopline Oct. 2026 41K 2L+ HNSCC (LiGeR-HN2) Data anticipated 1Q 2027 25K Locally advanced HNSCC Planned start 2026 70K 1L CRC (LiGeR-CRC1) Recruiting 78K** 2L+ CRC (LiGeR-CRC2) Recruiting 101K** *Estimated patients by line of therapy; US, EU, Japan. **RAS BRAF Wild Type Source: Genmab internal analysis. 3 Phase 3 trials announced/initiated since Merus acquisition in 2025 315K patients addressable across the petosemtamab Phase 3 program* Multi-$Bn peak sales opportunity For Investor audience only. Not for public information or use. Not for promotional use
Page 18
© Genmab 2026 04. Building Genmab’s Next Generation of Growth Three positive Phase 3 readouts create multiple potential approval and launch opportunities beginning in 2027, supporting a clear path towards sustainable, long-term growth
Page 19
© Genmab 2026 19 Positive Phase 3 Readouts Create Multiple Paths for Growth EPKINLY® Expansion plus Two Wholly Owned Assets Create Multiple Potential Approval and Launch Opportunities in 2027 EPKINLY® Co-developed with AbbVie PHASE 3 READOUT EPCORE® DLBCL-2 met its PFS endpoint in 1L DLBCL (HR 0.49). VALUE UNLOCK Potential 1L DLBCL expansion supports EPKINLY® as the core therapy in B-cell malignancies. >$3Bn peak sales potential Rina-S® Wholly owned PHASE 3 READOUT RAINFOL -02 met its primary PFS endpoint in PROC plus secondary endpoint of OS. Benefit in patients with PROC irrespective of FRα level or prior treatment with mirvetuximab. VALUE UNLOCK Potential first launch opportunity in PROC. >$2Bn peak sales potential Petosemtamab Wholly owned PHASE 3 READOUT At interim analysis LiGeR-HN1 met its dual endpoints of OS and ORR, regardless of HPV status. VALUE UNLOCK HNSCC anchors a wholly owned franchise, with two Phase 3 CRC expansion trials. Multi-$Bn peak sales potential Sources: Genmab Company Announcements. Peak sales: Genmab estimates. For Investor audience only. Not for public information or use. Not for promotional use
Page 20
genmab.com© Genmab 2026. All rights reserved.These materials may not be distributed orreproduced, in whole or in part, without permission from Genmab. Q&A